H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $15 from $11 and keeps a Buy rating on the shares after the company announced the acquisition of the U.S. rights to Amglidia.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter